NEW YORK (GenomeWeb News) — Celera said today it has licensed its estrogen/progesterone receptor patents to LabCorp, which will use the IP to commercialize two cancer tests.
The reference lab giant will use one test to predict risk of metastasis in early-stage breast cancer, while the other will assess hormone-receptor status to help plan endocrine therapy.
Under the agreement, LabCorp will pay Celera an up-front license fee and royalties on net sales of lab services and tests that use the IP.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.